Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
Rhea-AI Summary
Evolent Health (NYSE: EVH) will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026 after market close, followed by a conference call at 5:00 p.m. ET. Participants can listen via the company's investor relations website and analysts may dial in to ask questions. An audio playback will be available on the investor site for 90 days after the call.
Positive
- None.
Negative
- None.
News Market Reaction – EVH
In the Feb 4 session, EVH declined 0.97%, reflecting a mild negative market reaction. Argus tracked a trough of -6.2% from its starting point during tracking.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 02 | Inducement equity grant | Positive | +1.5% | CFO inducement RSU award of 587,500 shares vesting over three years. |
| Nov 06 | Strategic partnership | Positive | -5.5% | National cancer care model partnership with American Oncology Network. |
| Nov 06 | Earnings results | Positive | -5.5% | Q3 2025 results with higher 2025 revenue and EBITDA guidance. |
| Oct 09 | Earnings date | Neutral | +1.5% | Announcement of Q3 2025 reporting date and related conference call. |
| Sep 23 | Business divestiture | Positive | -2.3% | Sale of Evolent Care Partners for up to $113M and debt prepayment plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or strategic announcements often saw negative price reactions, while neutral scheduling or governance items sometimes coincided with modest gains.
Over the last few months, Evolent has reported strategic and financial milestones, including the divestiture of Evolent Care Partners for up to $113M on Sep 23, 2025 and Q3 2025 revenue of $479.5M on Nov 6, 2025 with updated 2025 guidance of $1.87B–$1.88B in revenue and adjusted EBITDA of $144M–$154M. Despite these developments, the stock often moved lower after earnings and strategic updates. Today’s earnings-date announcement for Q4 and year-end 2025 fits into this ongoing cadence of scheduled financial communications.
Key Terms
nyse financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.
An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
About Evolent
Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.
Contacts:
investorrelations@evolent.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-to-release-2025-fourth-quarter-and-year-end-financial-results-on-tuesday-february-24-2026-302679183.html
SOURCE Evolent Health, Inc.